Affymax Reviews

8 Reviews

3.7
8 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Affymax CEO and Director John Orwin
John Orwin
1 Rating

3 Employee Reviews Back to all reviews

Sort: Popular Rating Date
  1.  

    Good collaboration between departments, good benefits and bonuses.

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Anonymous Employee  in  Palo Alto, CA
    Former Employee - Anonymous Employee in Palo Alto, CA

    I worked at Affymax full-time for more than 8 years

    Pros

    Smart, intellectual workers, informative senior management from CEO to Director levels

    Cons

    One product company, with no prospective pipeline. Lost good people during commercial product failure. Joint meetings between departments were often confrontational, and difficult to sit for several hours.

    Advice to ManagementAdvice

    Have better clinical folks that can interpret patient data

    Recommends
    Positive Outlook
    Approves of CEO
  2.  

    Fair

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Career Opportunities
    Former Employee - Anonymous Employee
    Former Employee - Anonymous Employee

    I worked at Affymax

    Pros

    Good industry to be in

    Cons

    Poor management at senior levels

    Advice to ManagementAdvice

    Don't be so hierarchical with your technical staff

    No opinion of CEO
  3.  

    Future for Affymax after Hematide is murky

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Career Opportunities
    Former Employee - Research Associate IV  in  Palo Alto, CA
    Former Employee - Research Associate IV in Palo Alto, CA

    I worked at Affymax

    Pros

    It has a peptide drug for anemia that is likely to be approved by the FDA. The drug has efficacy, low cost of goods, and is a good candidate for Medicare preference for the treatment of anemia for the dialysis patient population. The safety profile and monthly administration of the drug is a big advantage over the currently marketed drugs for anemia.

    Cons

    No more research for new targets for new drugs in the pipeline. All work was focused on the one drug; what is next? Unless a new target is identified, there isn't much for people at Affymax to do. They already laid off 95% of the researchers, so all that history and expertise is gone. It seems to be solely focused on getting Hematide through the trials, and now that they are ready to submit data to the FDA, what happens to anyone who isn't in sales and marketing?

    Advice to ManagementAdvice

    Sell the company to Takeda and make some money for the stockholders, or start up R&D again. The latest worry about cardiovascular effects really caused the stock to tank. Can it be explained, or are there changes that can be made in the administration of Hematide that would ameliorate that effect? Try some positive spin in the marketing approach.

    Approves of CEO

Worked for Affymax? Contribute to the Community!

Your response will be removed from the review – this cannot be undone.